natgillin/translations-raw huggingface dataset:
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (za to skupino bolnikov opredeljeno kot CLcr 30-60 ml/min), se priporoča naslednji odmerek zoledronske kisline (glejte tudi poglavje 4.4), kot sledi:
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, reduced Zoledronic Acid Hospira doses are recommended (see also section 4.4).
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo naslednji zmanjšani odmerek zdravila Zoledronska kislina Hospira (glejte tudi poglavje 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, reduced Zometa doses are recommended (see also section 4.4).
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo nižje odmerke zdravila Zometa (glejte tudi poglavje 4.4).
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo naslednji odmerek zoledronske kisline (glejte tudi poglavje 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zoledronic acid Teva dose is recommended (see also section 4.4):
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo naslednji odmerek zdravila Zoledronska kislina Teva (glejte tudi poglavje 4.4).
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zoledronic Acid Teva dose is recommended (see also section 4.4):
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo naslednji odmerek zdravila Zoledronska kislina Teva (glejte tudi poglavje 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zometa dose is recommended (see also section 4.4):
Pri bolnikih z zasevki v kosteh, ki imajo pred začetkom zdravljenja blago do zmerno okvaro ledvic (opredeljeno za to skupino bolnikov kot CLcr 30–60 ml/min), priporočajo naslednji odmerek zdravila Zometa (glejte tudi poglavje 4.4):
In patients with BRAF V600K mutation positive metastatic melanoma (n=16) the response rate was 13% (95% CI: 0.0, 28.7) with a median duration of response of 5.3 months (95% CI: 3.7, 6.8).
Pri bolnikih z metastatskim melanomom z mutacijo BRAF V600K (n = 16) je bil delež odziva 13 % (95 % IZ: 0,0, 28,7) in mediano trajanje odziva 5,3 meseca (95 % IZ: 3,7, 6,8).
In patients with CAPS, the body produces excessive amounts of IL-1 beta.
Pri bolnikih s periodičnimi sindromi, povezanimi s kriopirinom, (CAPS) v telesu nastaja prevelika količina IL-1 beta.
In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered.
Pri bolnikih s srčnožilnimi boleznimi (npr. koronarno srčno boleznijo, Prinzmetalovo angino in srčnim popuščanjem) ter hipotenzijo je treba zdravljenje z zaviralci adrenergičnih receptorjev beta kritično oceniti in upoštevati možnost zdravljenja z drugimi zdravilnimi učinkovinami.
In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (< 2 standard deviation score (SDS)), who may be considered for one test.
Pri bolnikih z izoliranim pomanjkanjem rastnega hormona od otroštva dalje (brez dokazov bolezni osi hipotalamus–hipofiza ali obsevanja glave) je treba priporočiti dva dinamična testa, razen pri tistih z nizkimi koncentracijami insulinu podobnega rastnega dejavnika 1 (IGF-1, Insulin-Like Growth Factor-1) (< 2 standardna odklona (SDS, Standard Deviation Score)), pri katerih zadošča en test.
In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and lamivudine treated patients.
Pri bolnikih s kroničnim hepatitisom B niso opazili razlik v pojavnosti teh dogodkov, če so se bolniki zdravili s placebom ali lamivudinom.
In patients with chronic hepatitis C that were on stable methadone maintenance therapy and naïve to peginterferon alfa-2b, addition of 1.5 microgram/kg/week of PegIntron subcutaneously for 4 weeks increased R-methadone AUC by approximately 15 % (95 % Cl for AUC ratio estimate 103 – 128 %).
Pri bolnikih s kroničnim hepatitisom C, ki so bili na vzdrževalnem zdravljenju s stalnimi odmerki metadona in še niso prejemali peginterferona alfa-2b, se je pri dodatku zdravila PegIntron v odmerku 1,5 mikrograma/kg/teden subkutano v času 4 tednov, povečala vrednost AUC za R-metadon za približno 15 % (95 % IZ za oceno razmerja AUC 103 - 128 %).
In patients with chronic hepatitis C that were on stable methadone maintenance therapy and naïve to peginterferon alfa-2b, addition of 1.5 microgram/kg/week of ViraferonPeg subcutaneously for 4 weeks increased R-methadone AUC by approximately 15 % (95 % Cl for AUC ratio estimate 103 – 128 %).
Pri bolnikih s kroničnim hepatitisom C, ki so bili na vzdrževalnem zdravljenju s stalnimi odmerki metadona in še niso prejemali peginterferona alfa-2b, se je pri dodatku zdravila ViraferonPeg v odmerku 1,5 mikrograma/kg/teden subkutano v času 4 tednov, povečala vrednost AUC za R-metadon za približno 15 % (95 % IZ za oceno razmerja AUC 103 - 128 %).
In patients with chronic liver disease treated with eltrombopag there was an association between TEE and platelet counts ≥ 200,000µl.
Pri bolnikih s kronično boleznijo jeter, zdravljenih z eltrombopagom, je obstajala povezava med trombemboličnimi dogodki in številom trombocitov ≥ 200.000/µl.
In patients with chronic obstructive pulmonary diseases, fentanyl may have more severe adverse reactions.
Pri bolnikih s kroničnimi obstruktivnimi pljučnimi boleznimi ima lahko fentanil hujše neželene učinke.
In patients with chronic or accelerated phase CML who cannot tolerate other treatments or whose disease does not respond to them, the recommended dose is 400 mg twice a day.
Pri bolnikih s kronično ali pospešeno fazo kronične mieloične levkemije, ki ne morejo prenašati drugih zdravil ali pri katerih se bolezen ne odziva nanje, znaša priporočeni odmerek 400 mg dvakrat na dan.
In patients with chronic renal failure and clinically evident ischemic heart disease or congestive heart failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration.
Pri bolnikih s kronično ledvično okvaro in klinično jasno ishemično boleznijo srca ali s kongestivno srčno okvaro vzdrževana koncentracija hemoglobina ne sme presegati zgornje ciljne meje za koncentracijo hemoglobina.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
Pri bolnikih s kronično ledvično odpovedjo, pri katerih je intravenski dostop redno na razpolago (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Abseamed.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Binocrit by the intravenous route is preferable.
Pri bolnikih s kronično ledvično odpovedjo, pri katerih je intravenski dostop redno na razpolago (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Binocrit.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Epoetin alfa HEXAL by the intravenous route is preferable.
Pri bolnikih s kronično ledvično odpovedjo, pri katerih je intravenski dostop redno na razpolago (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Epoetin alfa HEXAL.
In patients with chronic renal failure, anaemia can be caused by a lack of erythropoietin.
Pri bolnikih s kronično ledvično odpovedjo je vzrok za anemijo lahko pomanjkanje eritropoetina.
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the haemoglobin concentration range as recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when ESAs were administered to achieve a haemoglobin concentration level of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično ledvično okvaro vzdrževalna koncentracija hemoglobina ne sme presegati zgornje meje razpona koncentracije hemoglobina, ki je priporočen v poglavju 4.2. V kliničnih preskušanjih so opazili povečano tveganje za smrt in resne kardiovaskularne dogodke, kadar so ESA dajali, da bi dosegli raven koncentracije hemoglobina, ki presega 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical studies, an increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično odpovedjo ledvic vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije, priporočene v poglavju 4.2. V kliničnih študijah so ugotovili večje tveganje smrti, resnih srčnožilnih dogodkov in trombote na žilnem dostopu, kadar so eritropoezo stimulirajoče agense (ESA) uporabljali tako, da je bil ciljni hemoglobin nad 120 g/l (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical studies, an increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično odpovedjo ledvic vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije, priporočene v poglavju 4.2. V kliničnih študijah so ugotovili večje tveganje smrti, resnih srčnožilnih dogodkov in tromboze na žilnem dostopu, kadar so eritropoezo stimulirajoče agense (ESA) uporabljali tako, da je bil ciljni hemoglobin nad 120 g/l (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical studies, an increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično odpovedjo ledvic vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije, priporočene v poglavju 4.2. V kliničnih študijah so ugotovili večje tveganje smrti, resnih srčnožilnih dogodkov, in tromboze na žilnem dostopu kadar so eritropoezo stimulirajoče agense (ESA) uporabljali tako, da je bil ciljni hemoglobin nad 120 g/l (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical studies, an increased risk of death, serious cardiovascular or cerebrovascular events including stroke, and vascular access thrombosis was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično odpovedjo ledvic vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije hemoglobina, priporočene v poglavju 4.2. V kliničnih študijah so ugotovili večje tveganje smrti ter resnih kardiovaskularnih in cerebrovaskularnih dogodkov, vključno z možgansko kapjo in trombozo na žilnem dostopu, če so ESA uporabljali tako, da je bil ciljni hemoglobin večji od 120 g/l (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events or cerebrovascular events including stroke was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično ledvično boleznijo vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije hemoglobina, priporočene v poglavju 4.2. V kliničnih preskušanjih so opazili povečano tveganje za smrt in resne srčnožilne dogodke ali cerebrovaskularne dogodke, vključno s kapjo, če je bila ciljna koncentracija hemoglobina dosežena z zdravili za stimulacijo eritropoeze nad 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death, serious cardiovascular events or cerebrovascular events including stroke were observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Pri bolnikih s kronično ledvično okvaro vzdrževalna koncentracija hemoglobina ne sme presegati zgornje meje priporočene ciljne koncentracije hemoglobina, ki je podana v poglavju 4.2. V kliničnih preskušanjih so opazili povečano tveganje za smrt, resne kardiovaskularne dogodke ali možgansko- žilne dogodke, vključno s kapjo, kadar so ESA dajali, da bi dosegli ciljno koncentracijo hemoglobina, ki presega 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, neutralising anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA) associated with epoetin theta therapy has been reported in post marketing setting.
Pri posameznih bolnikih s kronično ledvično odpovedjo so v obdobju trženja zdravila poročali o čisti aplaziji rdečih krvničk (PRCA – pure red cell aplasia), ki so jo sprožila nevtralizirajoča protitelesa proti eritropoetinu, in je bila povezana z zdravljenjem z epoetinom theta.
In patients with chronic renal failure, the maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when epoetins were administered to target a haemoglobin level in excess of 12 g/dl (7.45 mmol/l).
Pri bolnikih s kronično ledvično okvaro vzdrževalna koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije hemoglobina, priporočene v poglavju 4.2. V kliničnih preskušanjih so opazili povečano tveganje smrti in resnih kardiovaskularnih dogodkov, kadar so bile ob dajanju epoetina ciljne ravni hemoglobina višje od 12 g/dl (7,45 mmol/l).
In patients with chronic renal impairment whose creatinine clearance is < 30 ml/min and who are not receiving regularly scheduled haemodialysis, the recommended dose is reduced to either 1000 mg administered as a single infusion or 750 mg followed one week later by 375 mg (see section 5.2).
Pri pacientih s kronično okvaro delovanja ledvic, katerih kreatininski očistek je < 30 ml/min in ki ne prejemajo redno hemodialize, je priporočen odmerek dalbavancina zmanjšan na 1000 mg z enkratnim infundiranjem ali 750 mg, ki mu sledi 375 mg v naslednjem tednu (glej poglavje 5.2).
In patients with cirrhosis and in liver transplant recipients, treatment cessation is not recommended. (see section 5.1).
Pri bolnikih z cirozo in bolnikih s presajenimi jetri se prekinitev zdravljenja ne priporoča (glejte poglavje 5.1).
In patients with class II disease, Stayveer caused the resistance of the blood vessels to decrease by 23% compared with placebo after six months of treatment, but the distance the patients could walk over six minutes was similar in the two groups.
Pri bolnikih s pljučno arterijsko hipertenzijo razreda II je zdravilo Stayveer po šestih mesecih zdravljenja povzročilo zmanjšanje upornosti krvnih žil za 23 % v primerjavi s placebom, razdalja, ki so jo bolniki lahko prehodili v šestih minutah, pa je bila podobna v obeh skupinah.
In patients with class II disease, Tracleer caused the resistance of the blood vessels to decrease by 23% compared with placebo after six months of treatment, but the distance the patients could walk over six minutes was similar in the two groups.
Pri bolnikih z boleznijo II. funkcijskega razreda je zdravilo Tracleer po šestih tednih zdravljenja povzročilo 23-odstotno znižanje žilnega upora v primerjavi s placebom, vendar pa je bila razdalja, ki so jo bolniki lahko prehodili v šestih minutah, podobna v obeh skupinah.
In patients with CLL, tumour lysis syndrome (TLS) may occur with use of ofatumumab.
Pri bolnikih s KLL se lahko med uporabo ofatumumaba pojavi sindrom lize tumorja (TLS – tumor lysis syndrome).
In patients with CML in other phases (accelerated, myeloid blast and lymphoid blast) and in ALL, between a quarter and a third of the patients showed a complete response.
Pri bolnikih s KML v drugih obdobjih (obdobju pospešene rasti, mieloblastne preobrazbe in limfoblastne preobrazbe) in bolnikih z ALL se je na zdravljenje v celoti odzvala od četrtina do tretjina bolnikov.
In patients with compensated cirrhosis (e.g., Child-Pugh A), Pegasys has been shown to be effective and safe.
Pri bolnikih s kompenzirano cirozo (npr. stopnja Child-Pugh A) se je zdravilo Pegasys pokazalo kot učinkovito in varno zdravilo.
In patients with Crohn’s disease a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
Pri bolnikih s Crohnovo boleznijo so opazili tudi zmanjšanje števila celic, ki izražajo vnetne označevalce v kolonu, vključno z bistvenim zmanjšanjem ekspresije TNFα.
In patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
Pri bolnikih s Crohnovo boleznijo so opazili tudi zmanjšanje števila celic, ki izražajo vnetne označevalce v kolonu, vključno z bistvenim zmanjšanjem ekspresije TNFα.
In patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
Pri bolnikih s Crohnovo boleznijo so opazili tudi zmanjšanje števila celic, ki izražajo vnetne označevalce v kolonu, vključno z bistvenim zmanjšanjem ekspresije TNFα..
In patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
Pri bolnikih s Crohnovo boleznijo so opazili zmanjšanje števila celic, ki izražajo vnetne označevalce v kolonu, vključno z bistvenim zmanjšanjem ekspresije TNFα.
In patients with Crohn’s disease, adalimumab antibodies were identified in 7/269 subjects (2.6%) treated with adalimumab.
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 oseb (2,6%), ki so bile zdravljene z adalimumabom.
In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis.
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 oseb (2,6 %) in pri 18 od 487 (3,9 %) oseb z ulceroznim kolitisom.
In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis.
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 oseb (2,6 %) in pri 19 od 487 (3,9 %) oseb z ulceroznim kolitisom.
In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis.
Pri bolnikih s Crohnovo boleznijo so identificirali protitelesa proti adalimumabu pri 7 od 269 oseb (2,6 %) in pri 19 od 487 oseb (3,9 %) z ulceroznim kolitisom..
In patients with Crohn’s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5 g/ml during the induction period.
Pri bolnikih s Crohnovo boleznijo doseže polnilni odmerek 80 mg zdravila Humira na 0. teden, ki mu sledi 40 mg zdravila Humira 2. teden, med obdobjem indukcije najmanjšo koncentracijo v serumu približno 5,5 μg/ml.
In patients with Crohn’s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5 g/ml during the induction period.
Pri bolnikih s Crohnovo boleznijo doseže polnilni odmerek 80 mg zdravila Humira na 0. teden, ki mu sledi 40 mg zdravila Humira 2. teden, med obdobjem indukcije najmanjšo koncentracijo v serumu približno 5,5 g/ml.
In patients with Crohn’s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5 g/ml during the induction period.
Pri bolnikih s Crohnovo boleznijo doseže polnilni odmerek 80 mg zdravila Humira na 0. teden, ki mu sledi 40 mg zdravilo Humira 2. teden, med obdobjem indukcije najmanjšo koncentracijo v serumu približno 5,5 μg/ml.
In patients with current suicidal ideations and/or with a history of suicidal ideation and depressive disorder rimonabant should not be used unless the benefits of treatment are considered to outweigh these risks in an individual patient. (See section 4.3 and 4.8).
Pri bolnikih, ki imajo samomorilne misli in/ali bolnikih, ki so kdaj imeli samomorilne misli ali depresivno motnjo, se rimonabanta ne sme uporabljati, če koristi zdravljenja pri posameznem bolniku ne prevladajo nad temi tveganji (glejte poglavji 4.3 in 4.8).
In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).
Pri bolnikih z dekompenzirano jetrno boleznijo ali cirozo in pri bolnikih s presajenimi jetri prekinitev zdravljenja ni priporočljiva (glejte poglavje 5.1).
In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).
Pri bolnikih z dekompenzirano jetrno boleznijo ali z cirozo in pri bolnikih s presajenimi jetri prekinitev zdravljenja ni priporočljiva (glejte poglavje 5.1).